Stay updated with breaking news from Erich schmutzhard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ vasopharm GmbH ("vasopharm"), a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases,. ....
- Improved neurologic outcome in young adults (18-39 years) with Ronopterin infused early - Significantly less aggressive critical care with maintained renal function in young adults - ....
/PRNewswire/ vasopharm GmbH ("vasopharm"), a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases,. ....
vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study - Post-hoc analysis reveals clinically meaningful and statistically significant improvement in eGOS when Ronopterin is infused within 12 hours after trauma - But over the entire patient population trial did not meet its primary endpoint - vasopharm will communicate next steps after discussing these results with Competent Authorities - Further results to be published in a peer-reviewed journal - Currently there are no approved treatments for patients with moderate and severe traumatic brain injury News provided by Share this article Share this article WÜRZBURG, Germany, June 3, 2021 /PRNewswire/ vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announces that the NOSTRA III traumatic brain injury (TBI) Phase III clinical trial of ronopterin (VAS203) did not meet t ....